353 related articles for article (PubMed ID: 15616299)
1. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.
Muralidharan G; Micalizzi M; Speth J; Raible D; Troy S
Antimicrob Agents Chemother; 2005 Jan; 49(1):220-9. PubMed ID: 15616299
[TBL] [Abstract][Full Text] [Related]
2. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
[TBL] [Abstract][Full Text] [Related]
4. Exposure-response analyses of tigecycline tolerability in healthy subjects.
Passarell J; Ludwig E; Liolios K; Meagher AK; Grasela TH; Babinchak T; Ellis-Grosse EJ
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):123-9. PubMed ID: 19748422
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetic and pharmacodynamic profile of tigecycline.
Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S333-40. PubMed ID: 16080071
[TBL] [Abstract][Full Text] [Related]
6. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
Conte JE; Golden JA; Kelly MG; Zurlinden E
Int J Antimicrob Agents; 2005 Jun; 25(6):523-9. PubMed ID: 15885987
[TBL] [Abstract][Full Text] [Related]
7. Absence of an interaction between tigecycline and digoxin in healthy men.
Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
[TBL] [Abstract][Full Text] [Related]
8. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
10. Effect of tigecycline on normal oropharyngeal and intestinal microflora.
Nord CE; Sillerström E; Wahlund E
Antimicrob Agents Chemother; 2006 Oct; 50(10):3375-80. PubMed ID: 17005820
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.
Rello J
J Chemother; 2005 Aug; 17 Suppl 1():12-22. PubMed ID: 16285354
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis.
Korth-Bradley JM; Baird-Bellaire SJ; Patat AA; Troy SM; Böhmer GM; Gleiter CH; Buecheler R; Morgan MY
J Clin Pharmacol; 2011 Jan; 51(1):93-101. PubMed ID: 20308689
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of tigecycline in healthy volunteers.
Van Wart SA; Cirincione BB; Ludwig EA; Meagher AK; Korth-Bradley JM; Owen JS
J Clin Pharmacol; 2007 Jun; 47(6):727-37. PubMed ID: 17519399
[TBL] [Abstract][Full Text] [Related]
16. Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects.
Yamashita N; Matschke K; Gandhi A; Korth-Bradley J
J Clin Pharmacol; 2014 May; 54(5):513-9. PubMed ID: 24243316
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline: a critical analysis.
Stein GE; Craig WA
Clin Infect Dis; 2006 Aug; 43(4):518-24. PubMed ID: 16838243
[TBL] [Abstract][Full Text] [Related]
18. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults.
Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):190-9. PubMed ID: 23883872
[TBL] [Abstract][Full Text] [Related]
19. The glycylcyclines: a comparative review with the tetracyclines.
Zhanel GG; Homenuik K; Nichol K; Noreddin A; Vercaigne L; Embil J; Gin A; Karlowsky JA; Hoban DJ
Drugs; 2004; 64(1):63-88. PubMed ID: 14723559
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
